Halozyme Therapeutics, Inc. $HALO Shares Acquired by HRT Financial LP

HRT Financial LP boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 576.1% during the second quarter, HoldingsChannel reports. The fund owned 467,070 shares of the biopharmaceutical company’s stock after buying an additional 397,985 shares during the period. HRT Financial LP’s holdings in Halozyme Therapeutics were worth $24,296,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. DLD Asset Management LP purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth $650,250,000. Alliancebernstein L.P. boosted its position in shares of Halozyme Therapeutics by 4.8% during the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company’s stock worth $205,156,000 after purchasing an additional 146,677 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company’s stock valued at $132,192,000 after purchasing an additional 1,425,674 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Halozyme Therapeutics by 4.9% in the first quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company’s stock valued at $129,478,000 after purchasing an additional 95,600 shares during the period. Finally, LSV Asset Management lifted its stake in Halozyme Therapeutics by 40.2% during the second quarter. LSV Asset Management now owns 1,255,240 shares of the biopharmaceutical company’s stock worth $65,298,000 after purchasing an additional 360,049 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HALO. Morgan Stanley dropped their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research note on Monday, October 20th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a research report on Friday, November 28th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $75.10.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the sale, the director directly owned 42,952 shares in the company, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the transaction, the chief financial officer directly owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 83,625 shares of company stock valued at $5,932,527 over the last quarter. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Stock Up 0.5%

Shares of Halozyme Therapeutics stock opened at $62.21 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. Halozyme Therapeutics, Inc. has a 52-week low of $46.26 and a 52-week high of $79.50. The company has a market capitalization of $7.32 billion, a P/E ratio of 13.10, a P/E/G ratio of 0.33 and a beta of 0.95. The company has a 50 day moving average of $67.16 and a 200 day moving average of $64.55.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.27 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.